Late Intensification Therapy for Acute Leukemia in Remission: Chemotherapy and Immunotherapy

Gerald P. Bodey; Emil J. Freireich; Edmund Gehan; Kenneth B. McCredie; Victorio Rodriguez; Jordan Gutterman; M. Andrew Burgess

doi:10.1001/jama.1976.03260360023019

Late Intensification Therapy for Acute Leukemia in Remission: Chemotherapy and Immunotherapy

Gerald P. Bodey, Emil J. Freireich, Edmund Gehan, Kenneth B. McCredie, Victorio Rodriguez, Jordan Gutterman, M. Andrew Burgess

Leukemia

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

Nineteen patients In continuous complete remission of acute leukemia for at least one year received late Intensification therapy, after which they received no further chemotherapy, but most received BCG Immunotherapy. Five patients have relapsed. The 14 patients still in remission have been followed up for at least 60 weeks after late intensification, with a median time of 98 weeks. The length of complete remission subsequent to a comparable time was 44 weeks for a reference control group and 24 weeks for a matched control group. These results support this type of approach for long-term control of acute leukemia in adults.

Original language	English (US)
Pages (from-to)	1021-1025
Number of pages	5
Journal	JAMA: The Journal of the American Medical Association
Volume	235
Issue number	10
DOIs	https://doi.org/10.1001/jama.1976.03260360023019
State	Published - Mar 8 1976

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jama.1976.03260360023019

Cite this

@article{7a80dac3d0044a49a6ae0e19eeecd11c,

title = "Late Intensification Therapy for Acute Leukemia in Remission: Chemotherapy and Immunotherapy",

abstract = "Nineteen patients In continuous complete remission of acute leukemia for at least one year received late Intensification therapy, after which they received no further chemotherapy, but most received BCG Immunotherapy. Five patients have relapsed. The 14 patients still in remission have been followed up for at least 60 weeks after late intensification, with a median time of 98 weeks. The length of complete remission subsequent to a comparable time was 44 weeks for a reference control group and 24 weeks for a matched control group. These results support this type of approach for long-term control of acute leukemia in adults.",

author = "Bodey, {Gerald P.} and Freireich, {Emil J.} and Edmund Gehan and McCredie, {Kenneth B.} and Victorio Rodriguez and Jordan Gutterman and Burgess, {M. Andrew}",

year = "1976",

month = mar,

day = "8",

doi = "10.1001/jama.1976.03260360023019",

language = "English (US)",

volume = "235",

pages = "1021--1025",

journal = "JAMA: The Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "10",

}

TY - JOUR

T1 - Late Intensification Therapy for Acute Leukemia in Remission

T2 - Chemotherapy and Immunotherapy

AU - Bodey, Gerald P.

AU - Freireich, Emil J.

AU - Gehan, Edmund

AU - McCredie, Kenneth B.

AU - Rodriguez, Victorio

AU - Gutterman, Jordan

AU - Burgess, M. Andrew

PY - 1976/3/8

Y1 - 1976/3/8

N2 - Nineteen patients In continuous complete remission of acute leukemia for at least one year received late Intensification therapy, after which they received no further chemotherapy, but most received BCG Immunotherapy. Five patients have relapsed. The 14 patients still in remission have been followed up for at least 60 weeks after late intensification, with a median time of 98 weeks. The length of complete remission subsequent to a comparable time was 44 weeks for a reference control group and 24 weeks for a matched control group. These results support this type of approach for long-term control of acute leukemia in adults.

AB - Nineteen patients In continuous complete remission of acute leukemia for at least one year received late Intensification therapy, after which they received no further chemotherapy, but most received BCG Immunotherapy. Five patients have relapsed. The 14 patients still in remission have been followed up for at least 60 weeks after late intensification, with a median time of 98 weeks. The length of complete remission subsequent to a comparable time was 44 weeks for a reference control group and 24 weeks for a matched control group. These results support this type of approach for long-term control of acute leukemia in adults.

UR - http://www.scopus.com/inward/record.url?scp=0017301129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017301129&partnerID=8YFLogxK

U2 - 10.1001/jama.1976.03260360023019

DO - 10.1001/jama.1976.03260360023019

M3 - Article

C2 - 946184

AN - SCOPUS:0017301129

SN - 0098-7484

VL - 235

SP - 1021

EP - 1025

JO - JAMA: The Journal of the American Medical Association

JF - JAMA: The Journal of the American Medical Association

IS - 10

ER -

Late Intensification Therapy for Acute Leukemia in Remission: Chemotherapy and Immunotherapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this